The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.
 
Sathya Manoharan
No Relationships to Disclose
 
Mathias Bressel
No Relationships to Disclose
 
Paige James
No Relationships to Disclose
 
Yi-An Ko
No Relationships to Disclose
 
Anne L. Hamilton
No Relationships to Disclose
 
Clare L. Scott
Consulting or Advisory Role - Oncology One
Research Funding - AstraZeneca; Boehringer Ingelheim (Inst); Eisai; IDEAYA Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Illumina; MSD
(OPTIONAL) Uncompensated Relationships - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Linda R. Mileshkin
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - Roche
 
Marisa Grossi
No Relationships to Disclose
 
Nikki Burdett
No Relationships to Disclose
 
Sumitra Ananda
Honoraria - MSD
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Sanofi (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron; Sanofi
 
Paul J. Neeson
Research Funding - Allergan (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Crispr Therapeutics (Inst); ImmunOs Therapeutics (Inst); MSD (Inst); Roche/Genentech (Inst)
 
David Bowtell
Consulting or Advisory Role - Exo Therapeutics
Research Funding - AstraZeneca; BeiGene; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Henry Jackson Foundation INOVA HealthCare University of Melbourne (Inst)
 
George Au-Yeung
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)